Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States

Table 1 Patient demographic and clinical characteristics among all patients identified

Characteristic	VRd as first LOT (N = 2342)
Age at index date, years, mean (SD)	67.0 (10.0)
Age group, years, n (%)^a
< 65	836 (35.7)
65 to < 70	466 (19.9)
70 to < 75	443 (18.9)
≥ 75	597 (25.5)
Sex, n (%)^a
Female	1094 (46.7)
Male	1248 (53.3)
Race, n (%)^a
White	1363 (58.2)
Black or African American	411 (17.5)
Asian	51 (2.2)
Other	282 (12.0)
Unknown	235 (10.0)
ISS disease stage, n (%)^a
I	580 (24.8)
II	553 (23.6)
III	444 (19.0)
Unknown	765 (32.7)
ECOG PS score, n (%)^a
0	770 (32.9)
1	718 (30.7)
2	261 (11.1)
3	80 (3.4)
4	3 (0.0)
Unknown	510 (21.8)
Cytogenetic risk, n (%) ^a
High	374 (16.0)
Standard	1393 (59.5)
Unknown	575 (24.6)
Frail, n (%)^a	1122 (47.9)
Patients with CRAB symptoms, n (%)^a
Any	1175 (50.2)
Hypercalcemia	232 (9.9)
RI^b	250 (10.7)
Anemia	989 (42.2)
Bone disease	31 (1.3)
All	2 (0.1)
Year of index date, n (%)^a
2015	31 (1.3)
2016	410 (17.5)
2017	452 (19.3)
2018	495 (21.1)
2019	520 (22.2)
2020	388 (16.6)
January to February 2021	46 (2.0)
Diabetes, n (%)^a	211 (9.0)

VRd bortezomib, lenalidomide, and dexamethasone, LOT line of therapy, SD standard deviation, ISS International Staging System, ECOG PS Eastern Cooperative Oncology Group performance status, CRAB hypercalcemia, renal impairment, anemia, and bone disease, RI renal impairment, ICD-9-CM International Classification of Disease, 9th Revision, Clinical Modification; ICD-10-CM International Classification of Disease, 10th Revision, Clinical Modification
^aPercentages are calculated among all 2342 patients identified as receiving VRd as first LOT. Percentages may not add to 100 due to rounding
^bAcute RI, defined as patients with a serum creatinine > 2 mg/dL on the closest date to the index date or having diagnosis codes of ICD-9-CM 584.5-584.9, ICD-9-CM 586, ICD-10-CM N17.0-2, N17.8-9, and N19, measured ≤90 days prior to and ≤ 7 days after the index date

ISSN: 1471-2407